Chitosan modifies glycemic levels in people with metabolic syndrome and related disorders: meta-analysis with trial sequential analysis
Abstract Background Chitosan supplementation has been shown to modulate glycemic levels; however, studies have reported conflicting results. The present meta-analysis with trial sequential analysis was conducted to verify the overall influence of chitosan on glycemic levels in patients with metaboli...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2020-12-01
|
| Series: | Nutrition Journal |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12937-020-00647-4 |
| _version_ | 1818429658696253440 |
|---|---|
| author | Wenfang Guo Letai Yi Baochang Zhou Minhui Li |
| author_facet | Wenfang Guo Letai Yi Baochang Zhou Minhui Li |
| author_sort | Wenfang Guo |
| collection | DOAJ |
| description | Abstract Background Chitosan supplementation has been shown to modulate glycemic levels; however, studies have reported conflicting results. The present meta-analysis with trial sequential analysis was conducted to verify the overall influence of chitosan on glycemic levels in patients with metabolic syndrome. Methods The PubMed, Cochrane library, and EMBASE databases were systematically searched for randomized controlled studies of chitosan intake and glycemic levels. Results A total of ten clinical trials including 1473 subjects were included in this meta-analysis. Pooled effect sizes were determined by random-effects meta-analysis. Subgroup analysis was performed to analyze the sources of heterogeneity and their influence on the overall results. The results revealed a significant reduction in fasting glucose levels (SMD: − 0.39 mmol/L, 95% CI: − 0.62 to − 0.16) and hemoglobin A1c (HbA1c) levels (SMD: -1.10; 95% CI: − 2.15 to − 0.06) following chitosan supplementation but no effect on insulin levels (SMD: − 0.20 pmol/L, 95% CI: − 0.64 to 0.24). Subgroup analyses further demonstrated significant reductions in fasting glucose levels in subjects administered 1.6–3 g of chitosan per day and in studies longer than 13 weeks. Trial sequential analysis of the pooled results of the hypoglycemic effect demonstrated that the cumulative Z-curve crossed both the conventional boundary and trial sequential monitoring boundary for glucose and HbA1c. Conclusions The glucose level of patients who are diabetic and obese/overweight can be improved by supplementation with chitosan for at least 13 weeks at 1.6–3 g per day. Additional clinical research data are needed to confirm the role of chitosan, particularly in regulating glycosylated hemoglobin and insulin. |
| first_indexed | 2024-12-14T15:21:01Z |
| format | Article |
| id | doaj.art-bd2050f938124ea9bb33a83de469ee21 |
| institution | Directory Open Access Journal |
| issn | 1475-2891 |
| language | English |
| last_indexed | 2024-12-14T15:21:01Z |
| publishDate | 2020-12-01 |
| publisher | BMC |
| record_format | Article |
| series | Nutrition Journal |
| spelling | doaj.art-bd2050f938124ea9bb33a83de469ee212022-12-21T22:56:10ZengBMCNutrition Journal1475-28912020-12-0119111310.1186/s12937-020-00647-4Chitosan modifies glycemic levels in people with metabolic syndrome and related disorders: meta-analysis with trial sequential analysisWenfang Guo0Letai Yi1Baochang Zhou2Minhui Li3Inner Mongolia Autonomous Region Academy of Traditional MedicineInner Mongolia Autonomous Region Academy of Traditional MedicineInner Mongolia Medical UniversityInner Mongolia Autonomous Region Academy of Traditional MedicineAbstract Background Chitosan supplementation has been shown to modulate glycemic levels; however, studies have reported conflicting results. The present meta-analysis with trial sequential analysis was conducted to verify the overall influence of chitosan on glycemic levels in patients with metabolic syndrome. Methods The PubMed, Cochrane library, and EMBASE databases were systematically searched for randomized controlled studies of chitosan intake and glycemic levels. Results A total of ten clinical trials including 1473 subjects were included in this meta-analysis. Pooled effect sizes were determined by random-effects meta-analysis. Subgroup analysis was performed to analyze the sources of heterogeneity and their influence on the overall results. The results revealed a significant reduction in fasting glucose levels (SMD: − 0.39 mmol/L, 95% CI: − 0.62 to − 0.16) and hemoglobin A1c (HbA1c) levels (SMD: -1.10; 95% CI: − 2.15 to − 0.06) following chitosan supplementation but no effect on insulin levels (SMD: − 0.20 pmol/L, 95% CI: − 0.64 to 0.24). Subgroup analyses further demonstrated significant reductions in fasting glucose levels in subjects administered 1.6–3 g of chitosan per day and in studies longer than 13 weeks. Trial sequential analysis of the pooled results of the hypoglycemic effect demonstrated that the cumulative Z-curve crossed both the conventional boundary and trial sequential monitoring boundary for glucose and HbA1c. Conclusions The glucose level of patients who are diabetic and obese/overweight can be improved by supplementation with chitosan for at least 13 weeks at 1.6–3 g per day. Additional clinical research data are needed to confirm the role of chitosan, particularly in regulating glycosylated hemoglobin and insulin.https://doi.org/10.1186/s12937-020-00647-4ChitosanGlucoseInsulinHbA1cMeta-analysisTrial sequential analysis |
| spellingShingle | Wenfang Guo Letai Yi Baochang Zhou Minhui Li Chitosan modifies glycemic levels in people with metabolic syndrome and related disorders: meta-analysis with trial sequential analysis Nutrition Journal Chitosan Glucose Insulin HbA1c Meta-analysis Trial sequential analysis |
| title | Chitosan modifies glycemic levels in people with metabolic syndrome and related disorders: meta-analysis with trial sequential analysis |
| title_full | Chitosan modifies glycemic levels in people with metabolic syndrome and related disorders: meta-analysis with trial sequential analysis |
| title_fullStr | Chitosan modifies glycemic levels in people with metabolic syndrome and related disorders: meta-analysis with trial sequential analysis |
| title_full_unstemmed | Chitosan modifies glycemic levels in people with metabolic syndrome and related disorders: meta-analysis with trial sequential analysis |
| title_short | Chitosan modifies glycemic levels in people with metabolic syndrome and related disorders: meta-analysis with trial sequential analysis |
| title_sort | chitosan modifies glycemic levels in people with metabolic syndrome and related disorders meta analysis with trial sequential analysis |
| topic | Chitosan Glucose Insulin HbA1c Meta-analysis Trial sequential analysis |
| url | https://doi.org/10.1186/s12937-020-00647-4 |
| work_keys_str_mv | AT wenfangguo chitosanmodifiesglycemiclevelsinpeoplewithmetabolicsyndromeandrelateddisordersmetaanalysiswithtrialsequentialanalysis AT letaiyi chitosanmodifiesglycemiclevelsinpeoplewithmetabolicsyndromeandrelateddisordersmetaanalysiswithtrialsequentialanalysis AT baochangzhou chitosanmodifiesglycemiclevelsinpeoplewithmetabolicsyndromeandrelateddisordersmetaanalysiswithtrialsequentialanalysis AT minhuili chitosanmodifiesglycemiclevelsinpeoplewithmetabolicsyndromeandrelateddisordersmetaanalysiswithtrialsequentialanalysis |